Individuals Coming Off Weight-Loss Injections Put On Weight Four Times Faster Compared to People Using Diet and Exercise

A recent study reveals that individuals who come off blockbuster weight-loss injections like semaglutide or tirzepatide may regain reduced body mass at a significantly accelerated pace than those who end traditional lifestyle programs.

Findings released in a major medical journal shows that while obese people can lose about a fifth of their total mass while undergoing treatment, the mass comes back at an estimated rate of 0.8 kg per month once they quit.

"People using these drugs need to be cognizant of the risk of fast rebound weight gain when the medication is stopped," warns lead investigator Dr. Susan Jebb.

Such speed of regain implies a return to original weight within about a year and a half.

Weighing Approaches

The study, which reviewed dozens of trials involving thousands of participants, contrasted the effects of these new drugs with other pills.

Researchers point out that individuals who lose weight through diet and exercise usually have a less rapid creep back—perhaps 0.1 kg a month—after stopping.

Understanding the Fast Regain

Doctors propose the mechanism of the injections is key to understanding the amplified regain.

The injections imitate a natural hormone called GLP-1, which moderates appetite.

"Long-term administration of the hormone concentrations several times higher than normal may cause the system to generate a reduced amount of its own natural hormone, and may also reduce responsiveness to its effects," noted Dr. Adam Collins, a nutrition researcher.

"Discontinuation of this GLP-1 'fix' means hunger is no longer kept in check, making overeating much more probable."

An Ongoing Issue?

Medical guidelines recommend the injections for people with obesity-related medical conditions, accompanied by recommended lifestyle changes.

Many experts contend that, given the high risk of weight regain, the therapy is often ongoing.

This opinion is echoed by pharmaceutical companies, who state that the findings "emphasize the persistent character of excess weight," akin to managing diseases like high blood pressure.

Patient Accounts

Individuals who have stopped the jabs report a powerful resurgence of appetite.

"It was like a switch activating and I was suddenly starving," described one woman.

This challenge is exacerbated if patients have not established permanent dietary or behavioural modifications during treatment.

Widespread Interest

Figures indicate that a significant number of people in the UK have used weight-loss jabs in the last 12 months, with desire continuing to grow.

• Adoption is higher among women compared to men.
• The 40s and 50s demographic shows the greatest level of interest.
• A large proportion access the medications through private prescriptions rather than the NHS.

In conclusion, researchers stress that while these medications are powerful agents for weight loss, they are not a permanent cure and lasting health benefits relies on combined lifestyle changes.